Literature DB >> 19082635

C1q nephropathy and minimal change nephrotic syndrome.

Craig S Wong1, Christopher A Fink, Jane Baechle, Alexis A Harris, Amy O Staples, John R Brandt.   

Abstract

C1q nephropathy (C1qN) is an uncommon disorder seen in children and adults with nephrotic syndrome and non-specific urinary findings. It has been described with minimal change nephrotic syndrome (MCNS), focal segmental glomerulonephritis and isolated mesangial proliferative glomerulonephritis. We describe nine children with MCNS and mesangial C1q deposition. These children had a median age of 2.7 years at diagnosis (range 1.3-15 years), 56% were male and 78% were Hispanic. We compared these children to concurrent patients with nephrotic syndrome and biopsy-proven MCNS. We found that the C1qN patients were more likely than MCNS children to require chronic immunosuppression with calcineurin inhibitors or mycophenolate mofetil to maintain remission. However, all children were able to achieve and sustain clinical remission of nephrotic syndrome. Children with C1qN and minimal change histology have an increased frequency of frequently relapsing and steroid-unresponsive disease, but they can attain prolonged remission and stable renal function with calcineurin inhibitor or mycophenolate mofetil therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19082635     DOI: 10.1007/s00467-008-1058-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  22 in total

Review 1.  Distinguishing minimal-change disease from mesangial disorders.

Authors:  W A Border
Journal:  Kidney Int       Date:  1988-09       Impact factor: 10.612

2.  Eight and 12 week courses of cyclophosphamide in nephrotic syndrome.

Authors:  N Ueda; K Kuno; S Ito
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

3.  Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland.

Authors: 
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

4.  C1q nephropathy in two young sisters.

Authors:  Jameela A Kari; Sawsan M Jalalah
Journal:  Pediatr Nephrol       Date:  2007-10-21       Impact factor: 3.714

5.  A randomized study of two long-course prednisolone regimens for nephrotic syndrome in children.

Authors:  Masahiro Hiraoka; Hirokazu Tsukahara; Kousaku Matsubara; Masahito Tsurusawa; Nobuaki Takeda; Shinichi Haruki; Shuhei Hayashi; Kazuhide Ohta; Tohru Momoi; Yusei Ohshima; Narufumi Suganuma; Mitsufumi Mayumi
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

6.  Steroid-responsive nephrotic syndrome in a child with juvenile idiopathic arthritis.

Authors:  Flavio Bandin; Marion Merhenberger; Anne Modesto; Karine Brochard; Stéphane Decramer
Journal:  Pediatr Nephrol       Date:  2007-11-24       Impact factor: 3.714

7.  Clinicopathologic correlation of C1q nephropathy in children.

Authors:  Yuko Fukuma; Satoshi Hisano; Yoshie Segawa; Kazuhiko Niimi; Noboru Tsuru; Yoshitsugu Kaku; Ken Hatae; Yasuhiro Kiyoshi; Akihisa Mitsudome; Hiroshi Iwasaki
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

8.  C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome.

Authors:  J C Jennette; C G Hipp
Journal:  Am J Kidney Dis       Date:  1985-08       Impact factor: 8.860

9.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

10.  The treatment of minimal change nephrotic syndrome (lipoid nephrosis): cooperative studies of the Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN).

Authors:  J Brodehl; H P Krohn; J H Ehrich
Journal:  Klin Padiatr       Date:  1982 May-Jun       Impact factor: 1.349

View more
  6 in total

Review 1.  C1q nephropathy in the pediatric population: pathology and pathogenesis.

Authors:  Scott E Wenderfer; Rita D Swinford; Michael C Braun
Journal:  Pediatr Nephrol       Date:  2010-02-24       Impact factor: 3.714

2.  Do C1q or IgM nephropathies predict disease severity in children with minimal change nephrotic syndrome?

Authors:  Mateja Vintar Spreitzer; Alenka Vizjak; Dušan Ferluga; Rajko B Kenda; Tanja Kersnik Levart
Journal:  Pediatr Nephrol       Date:  2013-07-13       Impact factor: 3.714

Review 3.  Paediatric use of mycophenolate mofetil.

Authors:  Heather J Downing; Munir Pirmohamed; Michael W Beresford; Rosalind L Smyth
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

4.  C1q nephropathy in children: clinical characteristics and outcome.

Authors:  Vindya N Gunasekara; Neil J Sebire; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

5.  C1q nephropathy: a true immune complex disease or an immunologic epiphenomenon?

Authors:  Mordi Muorah; Manish D Sinha; Catherine Horsfield; Patrick J O'Donnell
Journal:  NDT Plus       Date:  2009-05-09

6.  C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics.

Authors:  Kipyo Kim; Hyung-Eun Son; Ji-Young Ryu; Hajeong Lee; Seung Hyeok Han; Dong-Ryeol Ryu; Jin Ho Paik; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Ho Jun Chin; Se Won Oh
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.